InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in late stage clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in discovery stage for use in the treatment of various immunological diseases. InDex Pharmaceuticals Holding AB (publ) was founded in 2015 and is headquartered in Solna, Sweden.